Cancer of Head and Neck
Conditions
Keywords
Quality of life, Radiotherapy, Dysphagia, Oral cavity, Oropharynx, Hypopharynx, Larynx, Swallowing rehabilitation, Toxicity
Brief summary
Toxicity and mainly dysphagia have increased in head and neck cancers as chemoradiation indications have risen over the last decade, leading to a significant loss of quality of life for patients. Recently, many retrospective studies and two evidence-based and systematic reviews on strategies to reduce radiation-induced dysphagia have suggested a trend toward benefit for a preventive swallowing exercise program. The main hypothesis of this study is that an early active swallowing therapy can improve the Quality of Life (QoL) of patients treated by radiotherapy for head and neck cancer. The study will be a randomized controlled, open-label, multicentric phase III clinical trial comparing early active swallowing therapy versus non specific swallowing management (usual care).
Detailed description
Patients in both groups will receive dietary and postural advice from the treating physician. Patients in the experimental group will be treated with an early active swallowing therapy including a consultation with a speech and language therapist twice a week and a detailed program of swallowing auto-exercises twice a day, from the start to one month after the end of radiotherapy. All speech therapists will be given precise guidelines based on the current state of the art and knowledge. All patients will be analyzed in intent-to-treat. Two ancillary studies will complete this global concept of the evaluation and prediction of severe alteration of Quality of Life (QoL) and Dysphagia. 1. A first study will evaluate videoradioscopy. Its objectives are to evaluate the ability of videoradioscopy at 3 months to predict poor QoL at 6 and 12 months, to identify videoradioscopic predictors of severe dysphagia, asymptomatic aspirations, cricopharyngeal stenoses and active swallowing rehabilitation efficiency. Each patient of both arms of the main study will undergo a videoradioscopy before the beginning of the radiation delivery (baseline evaluation), and at 3 and at 12 months. Data analysis will be centralized and will concern: APS (Aspiration and Penetration Scale) score, residue, Defective Laryngeal elevation, pharyngoesophageal sphincter dysfunction. Data will be correlated to the parameters of the main study in order to establish predictive models. 2. A second ancillary study will evaluate the dose-volume histograms of radiotherapy. The objectives are to identify predictors of dysphagia and of active swallowing rehabilitation efficiency, and to establish 2D and 3D predictive models of dysphagia. Imaging and dosimetric data (IMRT (Intensity Modified RadioTherapy) planning) and dose-volume histogram will be collected from the patients of the main clinical trial. Analysis will be centralized. Data will be correlated to the parameters of the main study in order to establish predictive models.
Interventions
OTHERSwallowing therapy
Patients will undergo active swallowing therapy with a speech and language therapist (twice a week) combined to a detailed program of swallowing auto-exercises (twice a day) from start of radiotherapy to one month after the end.
Sponsors
Rennes University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient treated for histologically proven head and neck cancer (oral cavity, oropharynx, or hypopharynx cancer) of stages I-IV or larynx cancer of stages II-IV, all histologic type, without distant metastasis * Indication of curative radiotherapy alone or associated to chemotherapy or targeted therapy, without planned surgery * WHO (World Health Organization) Performance Status 0, 1 or 2 * Sufficient cognitive capacities to complete a QoL questionnaire (evaluation by the physician at inclusion) * Written informed consent * Patients with health insurance
Exclusion criteria
* Previous radiotherapy or surgery of the upper aerodigestive tract * Cancer of paranasal sinuses or nasopharynx or skull base * Medical history of nervous system disease associated to significant sequelae in terms of dysphagia * Pregnant or breast-feeding woman * Patient under guardianship, trusteeship or judicial protection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients experiencing a clinically relevant improvement defined as a decrease of at least 10 points of the score HNSW ( 6 months after radiotherapy compared with the score before radiotherapy | 6 months after radiotherapy | HNSW = Head and Neck Swallowing Questionnaire |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| EORTC H&N35 score | Baseline, 3, 6 and 12 months after radiotherapy | EORTC H&N = European Organisation for Research and Treatment of Cancer Head and Neck questionnaire |
| MFI-20 score | Baseline, 3, 6 and 12 months after radiotherapy | MFI = Multidimensional Fatigue Inventory |
| Body Mass index (BMI) | Baseline, 3, 6 and 12 months after radiotherapy | in kg/m\^2 |
| Functional Oral Intake Scale (FOIS) | Baseline, 3, 6 and 12 months after radiotherapy | — |
| Overall duration of enteral nutrition | 12 months after radiotherapy | — |
| Total treatment duration | 12 months after radiotherapy | — |
| EORTC QLQ-C30 score | Baseline, 3, 6 and 12 months after radiotherapy | EORTC QLQ = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire |
| Number of patients with adverse events | End of radiotherapy (an average of 2 months after baseline), 1, 3, 6 and 12 months after radiotherapy | — |
| Swallowing specific Quality of Life (SWAL-QOL) score | Baseline, 3, 6 and 12 months after radiotherapy | — |
| Number of patients with aspiration and penetration determined by APS (Aspiration and Penetration Scale) scoring | Baseline, 3, 6 and 12 months after radiotherapy | — |
| Rate of global survival | 12 months after radiotherapy | — |
| Rate of survival without recurrence | 12 months after radiotherapy | — |
| Number of treatment interruptions | 12 months after radiotherapy | — |
Countries
France
Outcome results
None listed